drugset / Trial / NCT06734234

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234 ↗

Phase 1 Active not recruiting 86 enrolled GlaxoSmithKline
RandomizedSequentialTriple-blindTreatment

Summary

This is a study where a new drug, called GSK4771261 is being tested. Neither the study doctors, study staff or participants will be aware of what treatment is being given. Part A is testing the new study treatment on healthy people. This is to see if it's safe, what it does to the body, and how the body's defense system responds to it. Part B is similar, but the study treatment will be given to people who have a kidney disease called autosomal dominant polycystic kidney disease (ADPKD).

Timeline

Start
2024-12-11
Primary completion
2027-04-23
Completion
2027-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK4771261 Unknown — —

Indications